Company saved Americans more than $20 million on cold and flu treatments last season
SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is offering new savings on antivirals, medications and vaccines for the upcoming cold and flu season. Last flu season (October 1, 2022 through April 30, 2023), the CDC estimates that influenza was associated with more than 27 million illnesses, 300,000 hospitalizations, and 19,000 deaths, showing the importance of Americans taking preventative measures to protect themselves from the virus and understand the treatment options available if they get sick. With these significant savings, Americans can find affordable ways to prevent or treat seasonal illnesses, regardless of insurance status.
For live updates on the progression and treatment rates of the flu, COVID-19 and RSV, check out GoodRx’s “Tripledemic” Tracker.
Big Savings on Flu Shots
The best way for consumers to protect themselves against the flu is to get the annual flu shot between September and the end of October, notes the CDC. However, the typical out-of-pocket cost for a flu shot can be as high as $100, depending on the person’s location and the type of vaccine.
To make flu shots more accessible to all Americans this season, GoodRx is working directly with Walgreens, Walmart, and Weis to offer one flat rate that includes the vaccine and all admin fees, plus tax if applicable, with no surprise costs.
6 months to 64 years: Under $40 for the Fluarix or Fluzone Quadrivalent
65 years and older: Under $70 for the Fluzone High-Dose Quadrivalent
Cold & Flu Treatments
For those who get the flu this season, GoodRx is making it easy to access antivirals, which can shorten the duration and severity of the flu, and other medications to help treat symptoms and complications from the flu. Examples of savings on common treatments include:
Avg % Savings
(Pricing information based on September 2023 data and may vary at different pharmacies, and for different forms, dosages and quantities)
COVID-19 & RSV
In addition to cold and flu, GoodRx is helping Americans prepare for a rising number of COVID-19 and RSV cases. Trying to decide which vaccines to get and when can be overwhelming, so Dr. Preeti Parikh, Executive Medical Director of GoodRx, is providing the following advice:
Anyone six months and older should receive an annual flu shot by the end of October. Those 65 and older should get the high-dose version.
Adults with high-risk conditions and those 60 years and older should talk to their healthcare providers about the RSV vaccine, as they may be more susceptible to complications from the virus.
Parents of babies under the age of 8 months, or of babies ages 8 – 19 months old with high risk medical conditions, should talk to their pediatrician about getting the newly approved RSV antibody vaccine, starting October 1.
The flu and COVID vaccines can ideally be taken together, but Dr. Parikh recommends spacing out the RSV vaccine until more data is available to confirm that taking them together won’t decrease their efficacy.
Expert Advice from GoodRx Health
To help consumers better navigate this year’s “tripledemic,” GoodRx Health is offering a range of information and resources from its team of medical experts, including doctors and pharmacists.
To learn more about how GoodRx can help with the upcoming cold and flu season, visit: www.goodrx.com/cold-flu
GoodRx is a leading resource for healthcare savings and information that makes healthcare affordable and convenient for all Americans. We offer consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. Since 2011, we have helped consumers save over $60 billion and are one of the most downloaded medical apps over the past decade.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings and the benefits of our offerings to consumers. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits, changes in medication pricing and pricing structures, our reliance on a limited number of industry participants, the competitive nature of our industry, risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cyber-security and the important factors discussed in the sections entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and our other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.